BioTox scoops Bio-Quant as Apricus off-loads preclinical sectors
BioTox Sciences is flexing its drug discovery and preclinical testing muscle after acquiring Bio-Quant from its owner Apricus Biosciences.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs